2-(三氟甲基)吡咯烷盐酸盐 | 868623-97-6

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(三氟甲基)吡咯烷盐酸盐
• 英文名称: 2-(trifluoromethyl)pyrrolidine hydrochloride
• 英文别名: 2-Trifluoromethyl-pyrrolidine hydrochloride；2-(trifluoromethyl)pyrrolidine;hydrochloride
• CAS: 868623-97-6
• 化学式: C₅H₈F₃N*ClH
• 分子量: 175.581
• InChiKey: UAKBWWZKKFYLRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.72
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P301+P310,P305+P351+P338
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(三氟甲基)吡咯烷盐酸盐 在 碳酸氢钠 作用下， 以 水 为溶剂， 生成 2-(三氟甲基)吡咯烷
  参考文献：
  名称：

  The reaction of cyclic imines with the Ruppert–Prakash reagent. Facile approach to α-trifluoromethylated nornicotine, anabazine, and homoanabazine

  摘要：

  We have demonstrated that the Ruppert-Prakash reagent is able to react with a number of cyclic imines under acidic condition to afford the corresponding alpha-trifluoromethyl derivatives of nitrogen heterocycles. 5-7-Membered cyclic imines bearing various alkyl, aryl or heterocyclic group were successfully involved in this transformation. Novel trifluoromethylated analogues of nicotine, anabasine, and homoanabasine alkaloids were synthesized. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.11.032
• 作为产物：
  描述：

  2-(三氟甲基)吡咯烷 在 盐酸 作用下， 以 乙醚 、 水 为溶剂， 生成 2-(三氟甲基)吡咯烷盐酸盐
  参考文献：
  名称：

  The reaction of cyclic imines with the Ruppert–Prakash reagent. Facile approach to α-trifluoromethylated nornicotine, anabazine, and homoanabazine

  摘要：

  We have demonstrated that the Ruppert-Prakash reagent is able to react with a number of cyclic imines under acidic condition to afford the corresponding alpha-trifluoromethyl derivatives of nitrogen heterocycles. 5-7-Membered cyclic imines bearing various alkyl, aryl or heterocyclic group were successfully involved in this transformation. Novel trifluoromethylated analogues of nicotine, anabasine, and homoanabasine alkaloids were synthesized. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.11.032

文献信息

• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200102288A1

  公开（公告）日：2020-04-02

  Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了抑制WDR5和相关蛋白质-蛋白质相互作用的亚氨基-氮杂环-苯甲酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和状况的方法。
• [EN] INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL<br/>[FR] INHIBITION DU CANAL IONIQUE À POTENTIEL DE RÉCEPTEUR TRANSITOIRE A1
  申请人：HYDRA BIOSCIENCES INC

  公开号：WO2015164643A1

  公开（公告）日：2015-10-29

  The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

  本发明涉及式(I)化合物，或其药用盐、药物制剂或药物组合物，及其用于治疗疼痛、炎症性疾病、神经病、皮肤疾病、肺病状况和咳嗽，以及抑制瞬时受体电位Al离子通道(TRPA1)的应用。
• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Link T. James

  公开号：US20050277647A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• [EN] INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL<br/>[FR] INHIBITION DE CANAL IONIQUE À POTENTIEL DE RÉCEPTEUR TRANSITOIRE A1
  申请人：HYDRA BIOSCIENCES INC

  公开号：WO2016044792A1

  公开（公告）日：2016-03-24

  The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

  本发明涉及化合物的公式（I），或其药用可接受的盐或组合物，并其用于治疗疼痛、呼吸状况以及抑制瞬时受体电位Al离子通道（TRPA1）的方法。
• Impact of Fluoroalkyl Substituents on the Physicochemical Properties of Saturated Heterocyclic Amines
  作者：Kostiantyn P. Melnykov、Olha Tavlui、Artem Skreminskiy、Yuliya O. Kuchkovska、Oleksandr O. Grygorenko

  DOI：10.1002/chem.202201601

  日期：2022.10.4

  The replacement of azetidine, pyrrolidine, and piperidine with their fluoroalkyl-substituted analogs was shown to modulate basicity, lipophilicity and aqueous solubility. Comprehensive analysis of the obtained physicochemical data was carried out to guide rational fine-tuning of compounds’ properties related to drug optimization.

  用它们的氟烷基取代的类似物替代氮杂环丁烷、吡咯烷和哌啶显示出调节碱性、亲脂性和水溶性。对获得的理化数据进行综合分析，以指导合理微调与药物优化相关的化合物性质。